These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36746431)

  • 1. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
    Wang YH; Yao CY; Lin CC; Gurashi K; Amaral FMR; Bossenbroek H; Jerez A; Somervaille TCP; Binder M; Patnaik MM; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
    Br J Haematol; 2023 Apr; 201(2):302-307. PubMed ID: 36746431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
    Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
    Patnaik MM; Parikh SA; Hanson CA; Tefferi A
    Br J Haematol; 2014 May; 165(3):273-86. PubMed ID: 24467717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
    Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
    Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
    Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
    Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
    Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E;
    Br J Haematol; 2020 Mar; 188(5):605-622. PubMed ID: 31621063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
    Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
    Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients.
    Bou Samra E; Moreaux J; Vacheret F; Mills K; Rufflé F; Chiesa J; Piquemal D; Boureux A; Lavabre-Bertrand T; Jourdan E; Commes T
    Br J Haematol; 2012 May; 157(3):347-56. PubMed ID: 22390678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
    Hurtado AM; Luengo-Gil G; Chen-Liang TH; Amaral F; Batta K; Palomo L; Lumbreras E; Przychodzen B; Caparros E; Amigo ML; Dıez-Campelo M; Zamora L; Salido Fierrez EJ; Maciejewski JP; Ortuño FJ; Vicente V; Del Canizo M; Sole F; Ferrer-Marin F; Wiseman DH; Jerez A
    Br J Haematol; 2018 Aug; 182(3):373-383. PubMed ID: 29797327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.